Your Patients Need Cefepime — Here's How to Help Them Get It

The Cefepime shortage has put providers in a difficult position: you know the drug works, your patient needs it, and the pharmacy can't get it. Whether you're managing inpatients, coordinating OPAT discharges, or working in outpatient infectious disease, you need a reliable process for navigating supply disruptions.

This guide gives you five concrete steps to help your patients access Cefepime — plus alternative strategies and workflow tips to keep care moving even when supply doesn't cooperate.

Current Cefepime Availability

As of early 2026, Cefepime injection remains on the ASHP current shortage list. Manufacturing delays (notably from BBraun) and intermittent supply disruptions from multiple generic producers have made availability unpredictable across all formulations — 500 mg, 1 g, and 2 g vials, as well as pre-mixed IV bags.

The situation is fluid: a formulation that's available this week may not be next week, and regional variations are significant. Staying connected to real-time availability data is essential.

For the full shortage background, see Cefepime Shortage: What Providers and Prescribers Need to Know.

Why Patients Can't Find Cefepime on Their Own

Unlike oral medications, Cefepime is not stocked at retail pharmacies. Patients and caregivers who try to fill this prescription on their own face several barriers:

• No retail availability: Cefepime is an IV/IM injectable dispensed through hospital pharmacies, specialty pharmacies, and home infusion providers — not CVS or Walgreens.
• Shortage confusion: Patients may not understand that a drug shortage means limited supply across the entire market, not just at their specific pharmacy.
• Complex insurance billing: Specialty medications billed through medical benefit (vs. pharmacy benefit) can be confusing for patients navigating prior authorizations and out-of-pocket costs.
• Limited patient-facing information: Most drug shortage communications are aimed at pharmacists and healthcare systems, not patients.

What Providers Can Do: 5 Steps

Step 1: Check Real-Time Availability with Medfinder

Medfinder for Providers aggregates availability data for medications in shortage. Use it to:

• Search for Cefepime by formulation and strength
• Identify pharmacies and distributors with current stock
• Share availability information directly with your patient's pharmacy or home infusion provider

Integrating a Medfinder check into your prescribing workflow for shortage-affected drugs takes less than a minute and can save hours of phone calls.

Step 2: Coordinate with Your Hospital Pharmacy

Your pharmacy team is your most important partner during shortages. They can:

• Check availability across primary, secondary, and tertiary wholesalers
• Contact manufacturers directly for emergency allocation
• Source Cefepime in alternative vial sizes (e.g., using two 1 g vials instead of one 2 g vial)
• Verify whether pre-mixed IV bags are available when vials are not, or vice versa
• Coordinate with nearby health system pharmacies for inter-facility transfers

Step 3: Engage Your OPAT Coordinator

For patients transitioning to outpatient IV therapy, the OPAT coordinator plays a critical role:

• Identifying home infusion pharmacies with Cefepime in stock
• Coordinating supply before discharge — not after
• Arranging alternative infusion sites (infusion centers, hospital outpatient departments) if the home pharmacy can't source Cefepime
• Planning for supply interruptions with backup antibiotic orders

Step 4: Consider Alternatives Early

Don't wait until Cefepime is completely unavailable to consider alternatives. If supply is limited, proactive switching preserves remaining Cefepime for cases where it's truly the best option.

Common alternatives by indication:

• Febrile neutropenia: Piperacillin/Tazobactam 4.5 g IV q6h or Meropenem 1 g IV q8h
• Hospital-acquired pneumonia: Piperacillin/Tazobactam or Ceftazidime (with Pseudomonas coverage verification)
• Complicated UTI / pyelonephritis: Meropenem (especially for AmpC producers); Ceftriaxone for non-AmpC
• Intra-abdominal infections: Piperacillin/Tazobactam monotherapy or Meropenem

For a detailed comparison, share Alternatives to Cefepime with patients who have questions.

Step 5: Communicate Proactively with Patients

Patients and families are understandably anxious when they hear their medication is in shortage. Help by:

• Explaining the shortage in plain language — it's a manufacturing problem, not a problem with their care
• Sharing patient-friendly resources like Cefepime Shortage Update: What Patients Need to Know
• Discussing the alternative antibiotic plan and why it's appropriate for their infection
• Setting expectations for potential supply changes during their treatment course

Workflow Tips for Shortage Management

• Build shortage alternatives into your order sets: Work with your pharmacy and IT team to add conditional orders (e.g., "If Cefepime unavailable, substitute Piperacillin/Tazobactam") to your EHR order sets.
• Check availability before prescribing: A quick Medfinder search before writing the order can prevent delays and re-work.
• Track local supply trends: Ask your pharmacy to send weekly shortage updates to your department. Knowing which antibiotics are available this week shapes empiric choices.
• Document the reason for switching: In the medical record, note that the switch was necessitated by drug shortage, not clinical failure. This protects continuity of care and prevents confusion for follow-up providers.
• Plan discharge antibiotics early: For inpatients who will need outpatient IV antibiotics, start the pharmacy coordination process 48-72 hours before anticipated discharge.

Final Thoughts

Drug shortages are an unfortunate reality of modern healthcare, but they don't have to derail patient care. By staying informed, using tools like Medfinder for Providers, coordinating closely with pharmacy teams, and communicating openly with patients, you can navigate the Cefepime shortage effectively.

For the latest shortage data and prescribing implications, see our full provider shortage briefing.